Natural Alternatives shares rise 14.59% premarket on 13.8% sales growth and improved Q1 profitability.

Natural Alternatives International (NAII) surged 14.59% in premarket trading following the release of its Q1 2026 financial results, which highlighted a 13.8% year-over-year increase in net sales to $37.7 million, driven by a 17.7% rise in private-label contract manufacturing revenue. Despite a 33.9% decline in CarnoSyn® beta-alanine revenue, the company reported a narrowed net loss of $0.3 million (from $2.0 million) and generated income from operations for the first time in the quarter. CEO Mark Le Doux emphasized improved factory utilization, new customer growth, and the potential of TriBsyn™ in addressing healthcare trends linked to GLP-1 medications, while reaffirming guidance for full-year profitability. The upbeat results and forward-looking optimism aligned with the stock’s sharp premarket rally.